Vera Therapeutics (VERA) logo

Vera Therapeutics (VERA) stock

Immunological treatments , market cap $1.9B

After-hours Fri
$24.88
-2.24%

Close $25.45 -4.86%

Why is VERA down?

Down 1% on Nov 6, and still 16% under its Nov 5 close.

  • Its Nov 5 results: net loss widened to $93.7M, from $80.3M a year before. It fell 1% on Nov 6.

Sources: Price history, Nov 6, 2026; Company release, Nov 5, 2026

Tell me next time VERA moves

Free account, no card. An optional alert when VERA moves or its score changes.Pro, $1 for a first month. An optional alert when VERA moves or its score changes.Pro, 7 days free with a card. An optional alert when VERA moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on VERA →3 more reasons why VERA fell on Nov 6, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-6
Poor
In its industry
#197of 273
Checks firing
1of 14
Trending down
From 52-week high
-54.6%
under its best in a year

VERA's Quality Score fell 1 point on Fri, Nov 20, to -6. It closed away from its high of the day (2 chart checks stopped).

Follow VERA's trial news. Pro members can get an alert when Vera Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when VERA files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“Additional PIONEER clinical results expected in Q4 2026”Trial data · SEC filing · Aug 10
Cash$384M, about 4 quarters at the last year's spendingOn Sep 30

Key facts on VERA

Key facts on VERA
Holding it backA $415M loss wider than $252M a year earlier
Latest filing8-K, Nov 5 Reported its quarterly results
Cash$384M, about 4 quarters at the last year's spendingOn Sep 30

VERA catalysts

Coming up

After its last 4 reports it closed -1.4% on average, higher 1 of 4 times.

What's next for VERA, and how long its cash lasts

Next step the company has named

Q4 2026“Additional PIONEER clinical results expected in Q4 2026”Trial data · SEC filing · Aug 10

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
Atacicept in Multiple Glomerular DiseasesPhase 2 · Recruiting · 250 people · main data estimated Nov 2027 · NCT06983028

3 more trials, 2 more milestones and 39 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 4 quarters

$384M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Oct 28, 2024)
  • At-the-market share sales program (424B5, filed Aug 5, 2025)

For Pro members: 4 raises and their amounts, and the share count against a year ago.

Insiders

CEO Marshall Fordyce sold 18,500 shares on Sep 15, under a planned sale. 12 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Marshall Fordyce’s 27 filings and quotes.

Get an alert when VERA files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why VERA scores -6

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

-6 is below -5, off the left end of the scale.

  • +1Chart checks 1 of 14 firing right now, one point each
  • −3Long-term trend below a falling 200-⁠day average, down over one year, down over two years
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Persistence, and News.

What every line is worth, and the reason behind it, on VERA and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How VERA ranks in Biotech

VERA is #197 of 273 by Quality Score.

How VERA ranks in Biotech
RankStockQuality Score
197Vera Therapeutics (VERA) logoVERAVera Therapeutics-6

More in Biotech

When does VERA report earnings, and what happens after?

Expected to report Thu Feb 25, after the close (in 96 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What VERA reported on Nov 5, 2026

The quarter

A loss of $1.30 a share, from $1.26.

“The decrease was primarily due to a reduction in contract manufacturing expenses, as manufacturing costs for TRUTAKNA commercial supply, which were previously categorized as research and development expense, have been capitalized as inventory since its accelerated approval on July 7, 2026.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

VERA's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “Selling, general and administrative expenses were $61.4 million, compared with $27.5 million during the prior year period, reflecting investment in the commercial launch of TRUTAKNA.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value
$1.9B
today
Free cash flow
-$376M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on VERA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+1.6%-1.9%-4.1%-1.2%
Feb 26May 7Aug 10Nov 5
ReportedGapReaction5
days
Nov 5, 2026After close+1.1%-1.2%-3.6%
Aug 10, 2026After close+1.2%-4.1%+0.2%
May 7, 2026Before open-0.3%-1.9%+7.0%
Feb 26, 2026Before open-1.1%+1.6%-4.9%

VERA closed higher after 1 of its last 4 reports.

VERA has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on VERA, and all 14 on every stock.Get in free →See the top 3 →Start Pro

VERA RSI on Nov 20: 35.9, below its 50-day and 200-day averages

Not scored

RSI 35.9, MACD below signal, below both averages. Not scored.

7 more findings on VERA, each with its source, for Pro members.

VERA share count over time

13% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of VERA outstanding, as filed
Shares
outstanding
As
of
72.3MOct 29, 2026
72.1MJul 29, 2026
71.8MMay 1, 2026
63.9MOct 30, 2025
Offerings, shelves, and splits of VERA, from its filings
From its
filings
Filed
Raised $260.9M in a sale of shares, about 13% of its market valueDec 10, 2025
Set up an at-the-market program for up to $200M of shares, about 10% of its market valueAug 5, 2025
Raised $300M in a sale of shares, about 16% of its market valueOct 30, 2024
Registered shares for a later sale (S-3ASR)Oct 28, 2024

VERA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

3 more officers and directors file at VERA.

See insider trades by person

Which ETFs hold VERA?

In ETFs: VERA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Vera Therapeutics

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

362 employeesBrisbane, CAveratx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on VERA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn VERA's score around: 8 things
  • 6 more filings explained, a plain line each
  • Real-⁠time prices, no delay

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: VERA's Quality Score is -6 (Poor), #197 of 273 in Biotech.

What does VERA's Quality Score say?

VERA scores -6 today, which Breakaway calls Poor. It is #197 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 1% on Nov 6, and still 16% under its Nov 5 close. Cash lasts about 4 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is VERA's Quality Score?

VERA scores -6 today, which Breakaway calls Poor (below zero). That is #197 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind VERA's -6.

When does VERA report earnings?

Expected to report Thu Feb 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. VERA closed higher after 1 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Vera Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.